靶向树突状细胞的BCG疫苗增强抗结核保护效果
研究假设BCG与树突状细胞(DC)相互作用欠佳,遂工程化改造BCG表达靶向DC上DEC-205受体的单链可变片段(BCG:DEC)。小鼠实验显示BCG:DEC增强细胞摄取与细胞因子分泌,诱导更强多能CD4+ T细胞反应,并在攻毒后20周内提供优于BCG的保护。
要点
- BCG:DEC通过靶向DEC-205增强DC摄取与免疫激活。
- BCG:DEC诱导更高频率的多功能细胞因子分泌CD4+ T细胞。
- 小鼠攻毒后20周内BCG:DEC保护效果优于单独BCG。
核心结论
- 靶向树突状细胞的BCG:DEC是结核病控制的 promising 新策略。
研究设计与样本
- 研究为小鼠实验,工程化改造BCG表达靶向DEC-205受体的scFv(BCG:DEC),并与BCG比较免疫原性与保护效力。
主要发现
- BCG:DEC增强与表达DEC-205细胞的相互作用,增加宿主细胞摄取及细胞因子/趋化因子分泌。
- 接种小鼠后,BCG:DEC增加疫苗部位髓系细胞MHC-II表达,增强皮肤驻留DC亚群摄取,并产生更高频率的多功能细胞因子分泌CD4+ T细胞。
- 相比单独BCG,BCG:DEC在小鼠攻毒后20周内提供改善且持久的抗结核分枝杆菌保护。
临床怎么用
- 目前仅为小鼠临床前证据,尚不能直接指导人用预防接种实践。
局限性
- 原文摘要未报告样本量、具体保护效力数值及统计学参数。
- 研究限于小鼠模型,尚未在人体验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tuberculosis (TB) is the world's deadliest infectious disease, and the current vaccine, Bacillus Calmette-Guérin (BCG), is only partially effective. We hypothesised that BCG interacts sub-optimally with dendritic cells (DCs), key mediators of adaptive immunity. To improve BCG's efficacy, we engineered the vaccine to express a single-chain variable fragment (scFv) targeting the DEC-205 receptor on DCs (BCG:DEC). This modification enhanced BCG interaction with DEC-205-expressing cells, resulting in increased uptake into host cells and cytokine/chemokine secretion. After vaccination of mice, BCG:DEC increased MHC-II expression on vaccine-site myeloid cells, showed enhanced uptake by skin-resident DC subsets and generated higher frequencies of multifunctional, cytokine-secreting CD4+ T cell populations. Compared to BCG alone, BCG:DEC provided improved and sustained protection up to 20 weeks post-challenge against Mycobacterium tuberculosis in mice. Thus, DC-targeted BCG is a promising approach for TB control.
引用
- Counoupas C, Nisa A, Baker L, et al. Targeted delivery of the BCG vaccine to dendritic cells improves protective efficacy against Mycobacterium tuberculosis. Vaccine. 2026. PMID: 42172693. doi:10.1016/j.vaccine.2026.128753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。